SHH:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd · SHH · Healthcare · CNY · FY for 2025

Figures on this page computed 2026-11-07 23:41 UTC

Last close

n/aCNY

Market data

We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.

7.1xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
69.0%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
66.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
0.4%Dividend yield
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

Five bars, one line

lens 7 of 9

3.18x

5.79x

8.32x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

3 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales3.18x
Its own average over 10 years, 1.32B.
Profit5.79x
Its own average over 10 years, 500.4M.
Free cash flow8.32x
Its own average over 10 years, 335.3M.
Debtn/a
Its own average over 3 years, 83.4M.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at 8.32 times.

The filed years, as a table

Each line is 100 at 2016-12-31, the first year we hold.

Filed year	Sales	Profit	Shares in issue
2016-12-31	100.0	100.0	100.0
2017-12-31	114.8	145.0	100.9
2018-12-31	118.8	137.9	100.9
2019-12-31	122.5	85.5	105.4
2020-12-31	68.1	-81.1	116.2
2021-12-31	96.6	6.7	119.0
2022-12-31	85.9	18.4	121.8
2023-12-31	105.5	109.9	121.3
2024-12-31	124.2	262.8	122.2
2025-12-31	436.8	1,081.4	122.0

How sales was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How profit was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

How shares in issue was got

Source: computed
Statement: income
Fiscal year: 2025
Reported in: CNY

Figures behind the shape

Growth

45.0%

faster is higher, placed against 4,950 companies as of 2026-11-06

Five-year revenue growth rate45.0%
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
Five-year EPS growth raten/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
One-year change in net income311.5%
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed

Returns on capital

34.3%

higher is higher, placed against 5,089 companies as of 2026-11-06

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity34.3%
Net Income / Shareholders' Equity x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets32.4%
Net Income / Total Assets x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025

Margins

92.1%

wider is higher, placed against 3,412 companies as of 2026-11-06

Gross margin92.1%
Gross Profit / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin75.2%
Operating Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin69.0%
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin66.5%
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025

Price

7.1x

cheaper is higher, placed against 4,362 companies as of 2026-11-06

Price to earnings7.1x
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
Price to book2.4x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio4.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025

Safety

13.94

safer is higher, placed against 3,227 companies as of 2026-11-06

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio13.94
Current Assets / Current Liabilities
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage5545.1x
Operating Income / Interest Expense
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score25.92
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025

What it pays out

0.4%

more, and better covered, is higher, placed against 1,091 companies as of 2026-11-06

Dividend yield0.4%
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed
Payout ratio2.6%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Taken on
2026-11-07
Reported in
CNY
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio36.5x
Source
computed
Taken on
2026-11-07
Reported in
CNY
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.